NASDAQ · CMPS
Healthcare · Medical - Care Facilities
$13.45
Up+$0.16 (+1.20%)
Updated Aug 15, 2026, 3:58 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CMPS closed at $13.45 after 21 trading sessions, up 8.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $13.26 | $13.48 | $13.06 | $13.45 | 1.36M |
| Aug 13, 2026 | $14.20 | $14.20 | $13.28 | $13.29 | 2.39M |
| Aug 12, 2026 | $13.75 | $14.59 | $13.65 | $14.22 | 4.09M |
| Aug 11, 2026 | $13.48 | $13.69 | $13.20 | $13.38 | 2.19M |
| Aug 10, 2026 | $13.60 | $13.62 | $13.07 | $13.18 | 1.82M |
| Aug 7, 2026 | $13.51 | $14.08 | $13.26 | $13.54 | 3.39M |
| Aug 6, 2026 | $13.43 | $13.77 | $13.26 | $13.55 | 3.42M |
| Aug 5, 2026 | $11.60 | $13.6499 | $11.60 | $13.58 | 7.68M |
| Aug 4, 2026 | $11.35 | $11.87 | $11.20 | $11.80 | 2.37M |
| Aug 3, 2026 | $11.255 | $11.538 | $11.0208 | $11.25 | 2.77M |
| Jul 31, 2026 | $11.60 | $11.79 | $11.20 | $11.35 | 1.99M |
| Jul 30, 2026 | $10.92 | $11.60 | $10.83 | $11.57 | 1.97M |
| Jul 29, 2026 | $10.80 | $11.17 | $10.65 | $10.90 | 2.77M |
| Jul 28, 2026 | $11.20 | $11.3356 | $10.59 | $10.85 | 2.67M |
| Jul 27, 2026 | $11.26 | $11.77 | $11.205 | $11.27 | 2.98M |
| Jul 24, 2026 | $11.82 | $11.89 | $11.01 | $11.26 | 3.63M |
| Jul 23, 2026 | $11.80 | $11.9499 | $11.61 | $11.71 | 1.82M |
| Jul 22, 2026 | $12.05 | $12.20 | $11.85 | $11.93 | 1.73M |
| Jul 21, 2026 | $11.79 | $12.255 | $11.48 | $12.18 | 2.88M |
| Jul 20, 2026 | $12.16 | $12.39 | $11.635 | $11.67 | 5.58M |
| Jul 17, 2026 | $12.47 | $13.04 | $12.02 | $12.35 | 7.16M |
The latest Smart Investors Daily articles mentioning CMPS.
CMPS research
Company profile and research snapshot.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | B. Riley Securities | Buy | — |
| Jul 27, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.
Benzinga · Aug 6, 2026
Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
Benzinga · Aug 6, 2026
RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and lowers the price target from $22 to $21.
Benzinga · Aug 6, 2026
B. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $17 to $22.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CMPS.
